These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 22119911)

  • 1. Spatiotemporal effects of a possible chemorepulsion of tumor cells by immune system effectors.
    d'Onofrio A
    J Theor Biol; 2012 Mar; 296():41-8. PubMed ID: 22119911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune surveillance of human cancer: if the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune?
    Hamaï A; Benlalam H; Meslin F; Hasmim M; Carré T; Akalay I; Janji B; Berchem G; Noman MZ; Chouaib S
    Tissue Antigens; 2010 Jan; 75(1):1-8. PubMed ID: 20196816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor dormancy and immunoescape.
    Quesnel B
    APMIS; 2008; 116(7-8):685-94. PubMed ID: 18834412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL.
    Matsui S; Ahlers JD; Vortmeyer AO; Terabe M; Tsukui T; Carbone DP; Liotta LA; Berzofsky JA
    J Immunol; 1999 Jul; 163(1):184-93. PubMed ID: 10384115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antitumor immunity and cellular cancer therapies].
    Catros-Quemener V; Bouet F; Genetet N
    Med Sci (Paris); 2003 Jan; 19(1):43-53. PubMed ID: 12836191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The molecular biology of cancer. Part 2--Why cancers can outsmart our immune systems!
    Cohen HV; Quek SY
    J N J Dent Assoc; 2011; 82(2):34-6. PubMed ID: 21877656
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of CD200-CD200R in tumor immune evasion.
    Liao KL; Bai XF; Friedman A
    J Theor Biol; 2013 Jul; 328():65-76. PubMed ID: 23541619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MHC class I antigens, immune surveillance, and tumor immune escape.
    Garcia-Lora A; Algarra I; Garrido F
    J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macroimmunology and immunotherapy of cancer.
    Hamilton D; Ismail N; Kroeger D; Rudulier C; Bretscher P
    Immunotherapy; 2009 May; 1(3):367-83. PubMed ID: 20635957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural immunity to cancer in humans.
    Bindea G; Mlecnik B; Fridman WH; Pagès F; Galon J
    Curr Opin Immunol; 2010 Apr; 22(2):215-22. PubMed ID: 20207124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cellular automata model of tumor-immune system interactions.
    Mallet DG; De Pillis LG
    J Theor Biol; 2006 Apr; 239(3):334-50. PubMed ID: 16169016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simple biophysical model of tumor evasion from immune system control.
    d'Onofrio A; Ciancio A
    Phys Rev E Stat Nonlin Soft Matter Phys; 2011 Sep; 84(3 Pt 1):031910. PubMed ID: 22060406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Commentary: Immune escape versus tumor tolerance: how do tumors evade immune surveillance?
    Salih HR; Nüssler V
    Eur J Med Res; 2001 Aug; 6(8):323-32. PubMed ID: 11549514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human tumor-infiltrating lymphocytes: a marker of host response.
    Vose BM; Moore M
    Semin Hematol; 1985 Jan; 22(1):27-40. PubMed ID: 3155876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tumor-induced immunosuppression].
    Paul S; Calmels B; Régulier E
    Ann Biol Clin (Paris); 2002; 60(2):143-52. PubMed ID: 11937439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Escape from immune- and nonimmune-mediated tumor surveillance.
    Malmberg KJ; Ljunggren HG
    Semin Cancer Biol; 2006 Feb; 16(1):16-31. PubMed ID: 16140546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-mediated dormancy: an equilibrium with cancer.
    Teng MW; Swann JB; Koebel CM; Schreiber RD; Smyth MJ
    J Leukoc Biol; 2008 Oct; 84(4):988-93. PubMed ID: 18515327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor resistance to specific lysis: a major hurdle for successful immunotherapy of cancer.
    Chouaib S; Meslin F; Thiery J; Mami-Chouaib F
    Clin Immunol; 2009 Jan; 130(1):34-40. PubMed ID: 19013109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of immune escape of cancer and its regulation.
    Morita R; Hirohashi Y; Torigoe T
    Rinsho Ketsueki; 2009 May; 50(5):375-80. PubMed ID: 19483397
    [No Abstract]   [Full Text] [Related]  

  • 20. Tumor resistance to CD8+ T cell-based therapeutic vaccination.
    Huang Y; Shah S; Qiao L
    Arch Immunol Ther Exp (Warsz); 2007; 55(4):205-17. PubMed ID: 17659376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.